Absci (ABSI) to Release Quarterly Earnings on Tuesday

Absci (NASDAQ:ABSI) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Absci to post earnings of ($0.19) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Absci (NASDAQ:ABSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). Absci had a negative net margin of 2,838.89% and a negative return on equity of 44.24%. The business had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $2.05 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Up 2.0 %

Absci stock opened at $4.00 on Tuesday. The firm has a 50 day simple moving average of $4.01 and a 200 day simple moving average of $4.11. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.01. Absci has a 1-year low of $1.18 and a 1-year high of $6.72. The firm has a market capitalization of $454.24 million, a price-to-earnings ratio of -4.30 and a beta of 2.18.

Wall Street Analysts Forecast Growth

ABSI has been the topic of a number of analyst reports. KeyCorp decreased their price objective on Absci from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Guggenheim initiated coverage on Absci in a research report on Wednesday, October 2nd. They set a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Absci in a research report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.67.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.